Immune system via expression of HER2, Brachyury, and CD40L

The target 'Immune system via expression of HER2, Brachyury, and CD40L' refers to a multi-antigen immunotherapy strategy rather than a single molecular entity. This approach targets Human Epidermal Growth Factor Receptor 2 (HER2), a receptor tyrosine kinase frequently overexpressed in various cancers (UniProt P04626), and Brachyury, a transcription factor that drives epithelial-mesenchymal transition (EMT) and metastasis (UniProt O15178). The third component, CD40 Ligand (CD40L), is a costimulatory molecule that enhances the activation of antigen-presenting cells to trigger a robust T-cell mediated immune response (UniProt P29965). This combination is primarily delivered via the Tri-Ad5 vaccine platform (ETBX-011, ETBX-021, and ETBX-051), which uses adenovirus vectors to overcome immune tolerance and target heterogeneous tumor populations. By combining tumor-associated antigens with a potent immune stimulator, this strategy aims to improve clinical outcomes in patients with advanced or metastatic solid tumors (ImmunityBio, 2021; NCT03387501).

Other names

Tri-Ad5 vaccineETBX-011/021/051HER2-Brachyury-CD40L immunotherapyAd5-HER2/Ad5-Brachyury/Ad5-CD40L

This strategy utilizes viral vectors to deliver genetic sequences for HER2 and Brachyury to induce a polyvalent T-cell response against tumor-associated antigens, while simultaneously expressing CD40L to provide a costimulatory signal that activates dendritic cells and enhances the overall immune response (PubMed: 29439121, PubMed: 30104341).